A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

December 31, 2019

Conditions
Metastatic Breast Cancer
Interventions
DRUG

rucaparib

600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.

Trial Locations (2)

Unknown

Centre Leon Berard, Lyon

Institut Paoli Calmettes, Marseille

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Clovis Oncology, Inc.

INDUSTRY

collaborator

Fondation ARC

OTHER

lead

UNICANCER

OTHER